Life Sciences Update - February 2017

Life Sciences Update - February 2017

Welcome to our Life Science Issue, a monthly update from the Life Sciences team at S&B, containing news about recent and topical developments.

Contact our experts for further advice

View profile for Charlotte TillettCharlotte Tillett, View profile for Beverley FlynnBeverley Flynn, View profile for Gustaf DuhsGustaf Duhs
  1. Spotlight on pharmaceutical pricing

    New legislation currently before the House of Lords will clarify and extend Government powers to regulate pricing and require the industry to disclose more comprehensive pricing information. The legislation will impact companies at all stages of the... Read more
  2. Can you tell the difference between an app and a medical device?

    Health apps have surged in popularity recently and are now used daily on smartphones and tablets worldwide. In certain circumstances, health apps may be classified as medical devices and are therefore subject to a number of different regulatory requirements. The Medical and Healthcare products Regulatory Agency has recently published updated guidance, intended to assist app developers and manufacturers of medical devices in assessing whether their product is a medical device, and ultimately help ensure compliance.  

    Maliha Carey asks is your app a medical device and why does it matter?

    Read the article - published in Medical Plastics News

  3. New guidance for health and care professionals on confidentiality and data protection

    The Information Commissioner’s Office highlights data protection considerations arising out of the updated confidentiality guidance.

    Read more
  4. Department of Health launches arbitration and litigation panel

    Pharmaceutical companies are warned that The Department of Health is preparing to pursue claims through arbitration and the courts. The DOH recently launched a tender for a panel of law firms to act for it and identified the sort of claims that it had in mind. These include recovery of overpayments made to pharmaceutical companies, investigation into deceit, anti-competitive agreements and the abuse of a dominant position. The DOH appears to have pricing of pharmaceuticals, market distortions and price fixing in its sights. This makes it all the more important that pharmaceutical companies are sure that they can defend their pricing and marketing practices.

  5. Stevens & Bolton GDPR Seminar

    The new General Data Protection Regulation - is your business ready? 
    Data protection laws are about to undergo a radical change, which will affect all businesses, whatever their size, in all sectors. On 16th March our data protection lawyers will be hosting a GDPR seminar to look at some of the challenges faced by businesses arising from the new regulation and to help you create a road map for the future.

    To register, please email

Search our site